Exploring Semaglutide’s Impact on Knee Osteoarthritis and Weight
New findings from STEP 9 reveal significant pain and weight reduction benefits for OA patients.
Topline:
Recent results from the STEP 9 study highlight the potential of semaglutide, a GLP-1 receptor agonist, to facilitate significant weight loss and reduce knee pain in obese patients with knee osteoarthritis, marking a promising advancement in treatment options.
Study Details:
The STEP 9 study, discussed at the World Congress on Osteoarthritis 2024…
Keep reading with a 7-day free trial
Subscribe to Just Healthcare to keep reading this post and get 7 days of free access to the full post archives.